BioSpace News Archive

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2022 on Tuesday, November 8, 2022, after market close.

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2022 financial and operating results after market close on Tuesday, November 1st, 2022.

Bright Peak Therapeutics announced the formation of a Scientific Advisory Board comprised of world-renowned experts in immuno-oncology basic, translational and clinical research.

Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan.

Isoray Medical, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced they will hold an investor webcast Wednesday, October 19, 2022, at 4:15 p.m. EDT.

Denali Therapeutics Inc. announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering.

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, has amended terms of its loans with Richard Jeffs, the Company’s major shareholder and largest financier.

Origin Therapeutics Holdings Inc.(CSE: ORIG) (the “Company”, “Origin Therapeutics” or “Origin”) today announced that one of its portfolio companies, Clairvoyant Therapeutics (“Clairvoyant”), has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD) in Finland.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that it intends to offer and sell in an underwritten public offering, subject to market and other conditions, shares of common stock.